Short answer
Annexon, Inc. (ANNX) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$55M
- −12.6% YoY · −25.4% QoQ
- EPS (diluted)
- −$0.27
- +20.6% YoY · −17.4% QoQ
Source: XBRL data from the Annexon, Inc. (ANNX) Q2 2026 10-Q on SEC EDGAR. USD.
Annexon, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New debt risk triggered by July 30, 2026 Loan Agreement: $50 million funded, floating interest rate at least 7.60%
- Financial flexibility constrained by debt secured against substantially all assets and potential acceleration upon default
- Phase 3 ARCHER II regulatory risk: FDA may reject global trial data despite established U.S. and European registration path
- Near-term execution risk from expensive, multi-jurisdictional ARCHER II trial potentially delaying vonaprument development
- Liquidity risk with $209.2 million resources funding planned expenses into 2028 and additional capital needs possible sooner
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Annexon, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.